CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma

American Journal of Clinical Pathology

Volumn 130, Issue 5, 2008, Pages 724-730

  Bhargava, Rohit ^a   Beriwal, Sushil ^a   McManus, Kim ^a   Dabbs, David J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Breast basal like carcinoma; Cytokeratin 5; Cytokeratin 5 6; Immunohistochemistry

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN ANTIBODY;

ARTICLE; BREAST CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; ADULT; BASAL CELL CARCINOMA; BREAST TUMOR; GENE EXPRESSION PROFILING; IMMUNOLOGY; METHODOLOGY; PATHOLOGY;

ADULT; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KERATIN-5; KERATIN-6; SENSITIVITY AND SPECIFICITY;

EID: 55249099328     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP3KFF1LTYWQIY     Document Type: Article

References (26)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874.
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418-8423.
4. Honrado E, Benitez J, Palacios J. Histopathology of BRCA1-and BRCA2-associated breast cancer. Crit Rev Oncol Hematol. 2006;59:27-39.
5. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482-1485.
6. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25:5846-5853.
7. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271.
8. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
9. Reis-Filho JS, Simpson PT, Martins A, et al. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443:122-132.
10. Dabbs DJ, Chivukula M, Carter G, et al. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol. 2006;19:1506-1511.
11. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11:5175-5180.
12. Rakha E, Ellis I, Reis-Filho J. Are triple-negative and basal-like breast cancer synonymous [letter]? Clin Cancer Res. 2008;14:618.
13. Rakha EA, Tan DS, Foulkes WD, et al. Are triple-negative tumours and basal-like breast cancer synonymous [letter]? Breast Cancer Res. 2007;9:404.
14. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376.
15. McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716-721.
16. Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and HER2/neu-overexpressing phenotypes. Hum Pathol. 2006;37:1217-1226.
17. McCarthy A, Savage K, Gabriel A, et al. A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol. 2007;211:389-398.
18. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49:10-21.
19. Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11-24.
20. Moll R, Franke WW, Volc-Platzer B, et al. Different keratin polypeptides in epidermis and other epithelia of human skin: a specific cytokeratin of molecular weight 46,000 in epithelia of the pilosebaceous tract and basal cell epitheliomas. J Cell Biol. 1982;95:285-295.
21. Bocker W, Moll R, Poremba C, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest. 2002;82:737-746.
22. Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem. 1998;31:205-262.
23. Rakha EA, El-Sayed ME, Reis-Filho J, et al. Patho-biological aspects of basal-like breast cancer [published online ahead of print March 9, 2008]. Breast Cancer Res Treat. doi: 10.1007/s10549-008-9952-1.
24. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol. 2002;15:6-10.
25. Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001;116:823-830.
26. Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol. 1998;22:1215-1221.